We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $4.46B
This Fund
S&P 500
This Quarter Est. Return
-10.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
+$436M
Cap. Flow
+$887M
Cap. Flow %
31.35%
Top 10 Hldgs %
77.97%
Holding
321
New
50
Increased
109
Reduced
123
Closed
20

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$416M
2
JD icon
JD.com
JD
+$77.2M
3
PDD icon
Pinduoduo
PDD
+$71.2M
4
BIDU icon
Baidu
BIDU
+$68.2M
5
NTES icon
NetEase
NTES
+$43M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$4.5M
2
MSFT icon
Microsoft
MSFT
+$3.76M
3
TSLA icon
Tesla
TSLA
+$2.88M
4
BNO icon
United States Brent Oil Fund
BNO
+$2.69M
5
DBO icon
Invesco DB Oil Fund
DBO
+$2.63M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 60.57%
2 Communication Services 21.3%
3 Technology 8.32%
4 Healthcare 2.45%
5 Miscellaneous 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTRS icon
276
Viatris
VTRS
$18.8B
$167K 0.01%
12,354
+473
+4% +$6.32K
NVTA
277
DELISTED
Invitae Corporation
NVTA
$165K 0.01%
+10,779
New +$233K
OCGN icon
278
Ocugen
OCGN
$448M
$147K 0.01%
32,254
+8,145
+34% +$61.5K
INO icon
279
Inovio Pharmaceuticals
INO
$133M
$143K 0.01%
2,381
+574
+32% +$46K
OPK icon
280
Opko Health
OPK
$1.1B
$135K ﹤0.01%
28,039
-18,503
-40% -$74.9K
SRNE
281
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$129K ﹤0.01%
27,832
+6,068
+28% +$37.7K
CLVS
282
DELISTED
Clovis Oncology, Inc.
CLVS
$118K ﹤0.01%
43,630
+4,095
+10% +$15.1K
MNKD icon
283
MannKind Corp
MNKD
$1.27B
$116K ﹤0.01%
26,451
-1,325
-5% -$6.13K
ORGO icon
284
Organogenesis Holdings
ORGO
$224M
$116K ﹤0.01%
+12,549
New +$133K
GTHX
285
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$116K ﹤0.01%
11,327
-280
-2% -$3.57K
ALT icon
286
Altimmune
ALT
$605M
$109K ﹤0.01%
+11,936
New +$127K
IMGN
287
DELISTED
Immunogen Inc
IMGN
$100K ﹤0.01%
13,448
-3,350
-20% -$20.8K
CRIS icon
288
Curis
CRIS
$3.61M
$93K ﹤0.01%
49
-1
-2% -$2.38K
IBRX icon
289
ImmunityBio
IBRX
$8.53B
$90K ﹤0.01%
14,883
+2,245
+18% +$16.9K
MCRB icon
290
Seres Therapeutics
MCRB
$51.3M
$89K ﹤0.01%
537
-838
-61% -$133K
SGMO
291
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$88K ﹤0.01%
11,718
+672
+6% +$5.84K
KPTI icon
292
Karyopharm Therapeutics
KPTI
$42.4M
$80K ﹤0.01%
826
-542
-40% -$54K
RDUS
293
DELISTED
Radius Health, Inc.
RDUS
$74K ﹤0.01%
+10,757
New +$158K
VBIV
294
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$63K ﹤0.01%
894
+32
+4% +$2.7K
PGEN icon
295
Precigen
PGEN
$2.49B
$58K ﹤0.01%
+15,670
New +$67.4K
AKBA icon
296
Akebia Therapeutics
AKBA
$243M
$55K ﹤0.01%
24,397
-12,726
-34% -$34.7K
RIGL icon
297
Rigel Pharmaceuticals
RIGL
$868M
$43K ﹤0.01%
1,607
-48
-3% -$1.45K
VSTM icon
298
Verastem
VSTM
$654M
$38K ﹤0.01%
1,558
-437
-22% -$13.8K
VTGN icon
299
VistaGen Therapeutics
VTGN
$11.2M
$32K ﹤0.01%
540
+81
+18% +$5.27K
TCRT icon
300
Alaunos Therapeutics
TCRT
$4.06M
$29K ﹤0.01%
180
+29
+19% +$6.37K
9 10 11
12
13

Similar funds

ACM
Advent Capital Management New York $4.46B AUM 0.73% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
MAM
Magellan Asset Management Sydney, Australia $4.47B AUM 4.2% 1-Year Est. Return
AP
Americana Partners Houston, Texas $4.44B AUM 29.45% 1-Year Est. Return
BP
BC Partners New York $4.43B AUM 49.12% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
AOI
Auto-Owners Insurance Lansing, Michigan $4.43B AUM 30.05% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

E Fund Management's Q4 2021 Portfolio in Review

As of Q4 2021, E Fund Management held 321 positions worth $2.83B, up 18% from $2.39B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

E Fund Management deployed $887M of net new capital in Q4 2021, opening 50 new positions and adding to 109 existing holdings. Its largest new stake was Kanzhun: 1,105,207 shares worth $38.5M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 61% of assets, down from 62% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Apple, an estimated $4.5M trimmed.

  • E Fund Management's largest Q4 2021 buy was Kanzhun: 1,105,207 shares worth $38.5M.
  • E Fund Management added most to Alibaba in Q4 2021, an estimated $416M increase.
  • E Fund Management's biggest Q4 2021 reduction was Apple, cutting an estimated $4.5M.
  • E Fund Management fully exited Farfetch Limited Class A Ordinary Shares in Q4 2021, selling an estimated $379K.
  • E Fund Management's ten largest holdings make up 78% of its $2.83B portfolio in Q4 2021.
  • E Fund Management opened 50 new positions and closed 20 in Q4 2021.
  • E Fund Management's portfolio value rose 18% quarter-over-quarter to $2.83B.

Based on E Fund Management's 13F filing for Q4 2021, filed 11 Feb 2022.